Ayala Pharmaceuticals is a clinical-stage oncology company developing small molecule therapeutics for rare tumors and aggressive cancers. Its lead candidates include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), an anti-metabolite for acute myeloid leukemia treatment.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 100.0% |
| Net Debt/EBITDA | 100.0 |